Novartis Investigative Site

Prato, PO 59100

0 studies enrolling now · 6 studies all time

What they study most

Advanced HER2-positive Breast Cancer, Advanced Metastatic Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Psoriatic Arthritis

Studies at this site

• Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab — Completed
• Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis — Completed
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi — Stopped early
• Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) — Completed